Evaluating the result of cytoreductive surgery after neoadjuvant chemotherapy in advanced epithelial ovarian cancer

A retrospective study of 61 patients was conducted to evaluate the preliminary results of maximal cytoreductive surgery following neoadjuvant chemotherapy for FIGO stage IIIC-IV ovarian cancer from 2019 to 2023. The patients were diagnosed with FIGO staged IIIC (54.1%) and IV (45.9%), confirmed by preoperative histopathology. Elevated CA 125 level (> 1000 UI/ml) was found in 45 patients (73.8%). The rate of patients achieving optimal surgery was 80.4%. The mean surgery time was 134.1 ± 39.1 minutes, the average blood loss in 1 surgery was 171.2 ± 144.9mL. The drainage volume during the first 3 days was 115.4 ± 38.1mL. The patient started passing gas 3.9 ± 1.0 days after surgery, and started walking after 8.3 ± 2.0 days. The discharged day was 10.1 ± 2.1 days. After surgery, only 1 patient had intestinal obstruction, 2 patients had infection, 2 patients had bleeding, 1 patient had bladder dysfunction, and the remaining patients were stable postoperatively.